biostudies-literatureLust HNCI NIH HHS2763-2772https://www.ebi.ac.uk/biostudies/studies/S-EPMC12166372biostudies-literatureUnknown9(11)<h4>Abstract</h4>Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 chimeric antigen receptor T-cell therapy (CAR T) products for young adults (YA) with relapsed/refractory B-cell acute lymphoblastic leukemia. A distinct analysis of YAs receiving commercial CD19 CAR T has not been reported. Using retrospective data from the Pediatric Real-World CAR T Consortium and the Real-World Outcomes of CAR T in Adult ALL collaboration, we describe the efficacy and safety of tisa-cel and brexu-cel in 70 YAs (18-26 years; tisa-cel, n = 50; brexu-cel, n = 20). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were observed more frequently for brexu-cel vs tisa-cel (CRS, 85% vs 56%; ICANS, 40% vs 18%). Complete responseBlood advancesReal-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.PMC12166372P30 CA008748Bachanova VMiller KMcNerney KOYaghmour GCurran KJSatwani PJohn SBaumeister SHCJeyakumar NKopmar NEKumaran MVRaikar SSMuffly LRoloff GWFaramand RHall ELadha AHermiston MTalano JAAldoss IShaughnessy PBaggott CCooper SLOthman TZhang ASutherland KCKwon SQayed MFabrizio VALust HPhillips CLShah BDKarras NKota VKLuskin MRChen ECNguyen KMacMillan MAdvani ASSchultz LMRossoff JESchwartz MSTracy SCassaday RDMathews JMoskop AfalseReal-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.<h4>Abstract</h4>Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 chimeric antigen receptor T-cell therapy (CAR T) products for young adults (YA) with relapsed/refractory B-cell acute lymphoblastic leukemia. A distinct analysis of YAs receiving commercial CD19 CAR T has not been reported. Using retrospective data from the Pediatric Real-World CAR T Consortium and the Real-World Outcomes of CAR T in Adult ALL collaboration, we describe the efficacy and safety of tisa-cel and brexu-cel in 70 YAs (18-26 years; tisa-cel, n = 50; brexu-cel, n = 20). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were observed more frequently for brexu-cel vs tisa-cel (CRS, 85% vs 56%; ICANS, 40% vs 18%). Complete response2025-01-01T00:00:00Z2025 Jun2026-06-02T05:55:23.552Z2026-04-15T03:09:39.49ZS-EPMC121663724012739510.1182/bloodadvances.2024014846